Papers/PMID:38755622
The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
BMC complementary medicine and therapies2024The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Vitis vinifera — decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Also, the between-group analysis showed that the average changes in insulin serum levels and HOMA-IR and HOMA-β indices in the intervention group with GSE were significantly lower than the control group (0.97 ± 0.52 vs. 0.90 ± 0.03, p = 0.04; 57.80 ± 21.16 vs. 53.97 ± 11.14, p = 0.04).”
Quoted verbatim from The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.. - Study
- RCT
- Dose
- two 260 mg grape seed extract tablets daily (520 mg/day) for 2 months
- Population
- Adults aged 20-60 with non-alcoholic fatty liver disease (moderate to severe steatosis on ultrasound), BMI 25-35, in a double-blind placebo-controlled trial
The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.2024PMID:38755622Permalink